GlobeNewswire - News from Israel

Itamar Medical Announces Pricing of Public Offering of American Depositary Shares

Fri, 05 Feb 2021 14:44 GMT

CAESAREA, Israel, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the pricing of its public offering of 3,049,130 American Depositary Shares (“ADSs”) at a public offering price of $22.75 per ADS. The Company is selling 1,968,466 ADSs and one of its shareholders, Viola Growth 2 A.V. Limited Partnership (the “Selling Shareholder”), is selling 1,080,664 ADSs in the offering. Each ADS represents 30 ordinary shares of the Company. The gross proceeds to the Company from the offering are expected to be approximately $44.8 million and the gross proceeds to the Selling Shareholder from the offering are expected to be approximately $24.6 million, before deducting the underwriting discounts and commissions and other offering expenses payable by the Company. The Company and the Selling Shareholder have granted the underwriters a 30-day option to purchase up to an additional 457,369 ADSs in aggregate at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 9, 2021, subject to customary closing conditions.

CORRECTION – Itamar Medical Announces Proposed Offering of American Depositary Shares

Thu, 04 Feb 2021 22:16 GMT

CAESAREA, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, February 4th by Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), please note that the contact information was incorrect. The corrected release follows:

Itamar Medical Announces Proposed Offering of American Depositary Shares

Thu, 04 Feb 2021 21:01 GMT

CAESAREA, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the commencement of a proposed public offering of American Depositary Shares (“ADSs”) of the Company. Each ADS represents 30 ordinary shares of the Company. The ADSs to be sold in the offering will be offered by the Company and one of its shareholders, Viola Growth 2 A.V. Limited Partnership (the “Selling Shareholder”). The Company and the Selling Shareholder intend to grant to the underwriters a 30-day option to purchase up to an additional 15% of the ADSs being offered on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

RADA Schedules Fourth Quarter and Full Year 2020 Results Release & Conference Call on Wednesday, February 10, 2021

Thu, 04 Feb 2021 16:33 GMT

RADA’s investor conference call to start at 10am ET

RADA’s investor conference call to start at 10am ET

InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering

Thu, 04 Feb 2021 13:30 GMT

TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of $18 million (or $20.7 million if the underwriters exercise their option to purchase additional securities) prior to deducting underwriting discounts and estimated offering expenses payable by InspireMD.

CORPAC Awards Gilat Multi-Million-Dollar Contract to Provide Mission Critical Telecom Systems for Peru's Airports

Thu, 04 Feb 2021 12:09 GMT

PETAH TIKVA, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that it was awarded a multi-million-dollar contract to provide mission critical telecom systems for 29 of Peru's airports. The award of high-availability communication system was granted by CORPAC, the Peruvian Corporation of Commercial Airports and Aviation. This award follows Gilat's successful execution of large government projects and well positions Gilat for additional large deals in Peru.

DSP Group, Inc. Reports Fourth Quarter 2020 and Full Year Results

Thu, 04 Feb 2021 12:00 GMT

Fourth quarter revenues of $31.9 million, up 9% YoY, exceeding guidance
Record high fourth quarter non-GAAP gross margins of 51.9%

Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology

Thu, 04 Feb 2021 12:00 GMT

HINGHAM, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions. Japan is the second jurisdiction to grant a patent for the ‘One & Done’ guidewire technology and further protects the novel technology the Company is currently developing.

InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

Wed, 03 Feb 2021 13:32 GMT

New Chinese Distributor Will Also Invest in At-The-Market Private Placement

New Chinese Distributor Will Also Invest in At-The-Market Private Placement

Safe-T Group Ltd. to Participate at A.G.P.’s Virtual Emerging Growth Technology Conference on February 4, 2021

Wed, 03 Feb 2021 13:31 GMT

HERZLIYA, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Safe-T? Group Ltd. (NASDAQ, TASE: SFET), a provider of secure access solutions and intelligent data collection, today announced that Shachar Daniel, CEO of Safe-T Group, will be available to meet on a one-on-one basis at A.G.P.’s Virtual Emerging Growth Technology Conference on Thursday, February 4, 2021.

Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update

Wed, 03 Feb 2021 12:55 GMT

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021

Wed, 03 Feb 2021 12:00 GMT

REHOVOT, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2020, prior to the open of the U.S. financial markets on Wednesday, February 10, 2021.

Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering

Tue, 02 Feb 2021 13:30 GMT

HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced?it has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering, for gross proceeds of $30 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about February 4, 2021, subject to the satisfaction of customary closing conditions.

RADA Joins TASE’s Dual Listed Companies

Mon, 01 Feb 2021 18:18 GMT

The shares of the company, which are currently listed on NASDAQ (NASDAQ: RADA), will also be traded on The Tel Aviv Stock Exchange (TASE: RADA) starting on February 2, 2021

The shares of the company, which are currently listed on NASDAQ (NASDAQ: RADA), will also be traded on The Tel Aviv Stock Exchange (TASE: RADA) starting on February 2, 2021

Gilat Awarded Contract with a Potential of Over $50 Million to Supply Wavestream’s Gateway Solid State Power Amplifiers for Low Earth Orbit Constellation

Mon, 01 Feb 2021 12:16 GMT

PETAH TIKVA, Israel, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that its subsidiary Wavestream received an award estimated at more than $50M from a leading satellite operator to support the gateways for a Low Earth Orbit (LEO) broadband satellite constellation. Wavestream has been selected to supply Gateway Solid State Power Amplifiers (SSPAs) for the project.

Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA

Mon, 01 Feb 2021 12:00 GMT

Transaction Represents Kamada’s Entry into U.S. Plasma Collection Market and Advances the Company’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company

Israeli Groundbreaking Technology by Saffron Tech Challenges Iranian 1,000-Year Monopoly on the Lucrative $1B Saffron Market

Thu, 28 Jan 2021 17:45 GMT

TEL AVIV, Israel, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Saffron Tech, an Israeli wholly owned subsidiary of Seedo Corp. (OTCQB: SEDO), announced its technology for automated, year-round saffron growing, is challenging the global Iranian monopoly on saffron supply of 90-95% of world demand, which has been in place for the past 1,000 years!

Playtika Announces Date of Fourth Quarter 2020 Results Conference Call

Thu, 28 Jan 2021 14:00 GMT

HERZLIYA, Israel, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Playtika Holding Corp. (NASDAQ:PLTK) announced today it will release financial results for the fourth quarter 2020 before U.S. markets open on Thursday, February 25, 2021.

Water Ways Announces a CAD$233,000 Order for Its Medical Cannabis IOT Precise Irrigation and Fertilization System

Thu, 28 Jan 2021 13:41 GMT

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES?OR DISSEMINATION IN?THE?UNITED STATES

IceCure Announces a $15 Million Private Placement and Intention to Pursue NASDAQ Listing

Thu, 28 Jan 2021 13:00 GMT

Upon closing, the company to meet Nasdaq listing requirements without the need to effect a concurrent public offering; funds to enable the company to expand the commercialization of its products in existing and new markets and accelerate development of new products in the coming year